Introduction:

Venlafaxine was the first the first serotonin norepinephrine reuptake inhibitor antidepressant to authorized in Spain. Although there is no indication in the data sheet in the treatment of neuropathic pain, there are clinical practice guidelines in which venlafaxine appears in the first or second line of treatment.

Development:

Following a literature search, this article summarizes the most relevant pharmacological data of venlafaxine, as well as the specific literature of this drug in neuropathic pain.

Conclusions:

Venlafaxine is a safe and well tolerated drug for the symptomatic treatment of neuropathic pain. Although the current evidence is quite encouraging (at doses of at least 150 mg/day), further research is needed to extend these findings, particularly when is compared to other possible pharmacological agents.

        · |     · |     · ( pdf )